Compare Alliant Energy Corporation (LNT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Novavax Inc — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Alliant Energy Corporation is far larger — about 9.3× Novavax Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Novavax Inc for 59 Days on average.
| LNT | NVAX | |
|---|---|---|
Market Cap | $16.99B | $1.82B |
Volume | 2,488,387 | 6,198,505 |
Sector | Utilities | Health |
52-Week High | $78.03 | $12.56 |
52-Week Low | $63.21 | $6.22 |
Typical Hold Time | 64 Days | 59 Days |
Enterprise Value | $29.08B | $1.39B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $65.50, up 0.44% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $0.65 and consistent revenue growth to $4.36B in 2025. Analyst consensus is positive with a $77.00 price target and 52% buy ratings. Recent institutional activity includes significant purchases by California State Teachers Retirement System and Nykredit A/S.
LNT presents a compelling investment case with stable utility operations, 23-year dividend growth, and a $13.4B capital investment plan supporting 5-7% earnings growth. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and sensitivity to interest rate changes. The stock offers defensive value with current momentum favoring upside toward analyst targets.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
